Characteristics and Long-Term Follow-Up of Participants with Peripheral Arterial Disease During ALLHAT
详细信息 查看全文
- 作者：Linda B. Piller MD ; MPH (1) <br> Lara M. Simpson PhD (1) <br> Sarah Baraniuk PhD (1) <br> Gabriel B. Habib MD (2) <br> Mahboob Rahman MD (3) <br> Jan N. Basile MD (4) <br> Richard A. Dart MD (5) <br> Allan J. Ellsworth PharmD (6) <br> Herbert Fendley MD (7) <br> Jeffrey L. Probstfield MD (8) <br> Paul K. Whelton MB. ; MD ; MSc. (9) <br> Barry R. Davis MD ; PhD (1) <br> for the ALLHAT Collaborative Research Group <br>
- 关键词：cardiovascular disease ; hypertension ; clinical trials
- 刊名：Journal of General Internal Medicine
- 出版年：2014
- 出版时间：November 2014
- 年：2014
- 卷：29
- 期：11
- 页码：1475-1483
- 全文大小：405 KB
- 参考文献：1. Murabito JM, D鈥橝gostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the Framingham Heart Study. Circulation. 1997;96:44鈥?9. blank" title="It opens in new window">CrossRef <br> 2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999鈥?000. Circulation. 2004;110:738鈥?43. blank" title="It opens in new window">CrossRef <br> 3. Bozkurt AK, Tasci I, Tabak O, Gumus M, Kaplan Y. Peripheral artery disease assessed by ankle-brachial index in patients with established cardiovascular disease or at least one risk factor for atherothrombosis鈥揅AREFUL study: a national, multi-center, cross-sectional observational study. BMC Cardiovasc Disord. 2011;11:4. blank" title="It opens in new window">CrossRef <br> 4. Meijer WT, Grobbee DE, Hunink MGM, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000;160:2934鈥?938. blank" title="It opens in new window">CrossRef <br> 5. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med. 1998;3:241鈥?45. blank" title="It opens in new window">CrossRef <br> 6. Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13:209鈥?15. blank" title="It opens in new window">CrossRef <br> 7. Antonopoulos S, Kokkoris S, Stasini F, et al. High prevalence of subclinical peripheral artery disease in Greek hospitalized patients. Eur J Intern Med. 2005;16:187鈥?91. blank" title="It opens in new window">CrossRef <br> 8. Cacoub PP, Abola MT, Baumgartner I, et al. REACH Registry Investigators. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the REduction of Atherothrombosis for Continued Health (REACH) registry. Atherosclerosis. 2009;204:e86鈥揺92. blank" title="It opens in new window">CrossRef <br> 9. Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des. 2004;10:3615鈥?620. blank" title="It opens in new window">CrossRef <br> 10. De Buyzere ML, Clement DL. Management of hypertension in peripheral arterial disease. Prog Cardiovasc Dis. 2008;50:238鈥?63. blank" title="It opens in new window">CrossRef <br> 11. Singer DR, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter? Eur J Vasc Endovasc Surg. 2008;35:701鈥?08. blank" title="It opens in new window">CrossRef <br> 12. Lauer MS. Comparative effectiveness research: the view from the NHLBI. J Am Coll Cardiol. 2009;53:1084鈥?086. blank" title="It opens in new window">CrossRef <br> 13. Matchar DB, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16鈥?9. blank" title="It opens in new window">CrossRef <br> 14. Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171:384鈥?94. <br> 15. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206鈥?252. blank" title="It opens in new window">CrossRef <br> 16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981鈥?997. blank" title="It opens in new window">CrossRef <br> 17. Cushman WC, Davis BR, Pressel SL, ALLHAT Collaborative Research Group, et al. Mortality and morbidity during and after the Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012;14:20鈥?1. blank" title="It opens in new window">CrossRef <br> 18. The fifth report of the Joint National Committee On Detection. Evaluation, and treatment of high blood pressure (JNC V). Arch Int Med. 1993;153:154鈥?83. blank" title="It opens in new window">CrossRef <br> 19. Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342鈥?60. blank" title="It opens in new window">CrossRef <br> 20. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239鈥?46. blank" title="It opens in new window">CrossRef <br> 21. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Protocol. Available at: https://allhat.sph.uth.tmc.edu/Forms/protocol.pdf. Accessed April 28, 2014 <br> 22. Klein JP, Moeschberger ML. Survival Analysis: Techniques for Censored and Truncated Regression. 2nd ed. New York, NY: Springer; 2003. <br> 23. Stafylas PC, Sarafidis PA. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4:23鈥?0. blank" title="It opens in new window">CrossRef <br> 24. Espinola-Klein C, Weisser G, Jagodzinski A, et al. 脽-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148鈥?54. blank" title="It opens in new window">CrossRef <br> 25. Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48鈥?3. blank" title="It opens in new window">CrossRef <br> 26. Hirsch AT, Duprez D. The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease. Vasc Med. 2003;8:273鈥?78. blank" title="It opens in new window">CrossRef <br> 27. Coppola G, Romano G, Corrado E, Grisanti RM, Novo S. Peripheral artery disease: potential role of ACE-inhibitor therapy. Vasc Health Risk Manag. 2008;4:1179鈥?187. <br> 28. Ostergren J, Sleight P, Dagenais G, et al. HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25:17鈥?4. blank" title="It opens in new window">CrossRef <br> 29. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144:660鈥?64. blank" title="It opens in new window">CrossRef <br> 30. Gey DC, Lesho EP, Manngold J. Management of peripheral arterial disease. Am Fam Physician. 2004;69:525鈥?32. <br> 31. Hirsch AT, Haskal ZJ, Hertzer NR, American Association for Vascular Surgery, Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, ACC/AHA Task Force on Practice Guidelines, American Association of Cardiovascular and Pulmonary Rehabilitation, National Heart, Lung, and Blood Institute, Society for Vascular Nursing, TransAtlantic Inter-Society Consensus, Vascular Disease Foundation, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary. J Am Coll Cardiol. 2006;47:1239鈥?312. blank" title="It opens in new window">CrossRef <br> 32. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, Burt V, Curtin L, Engelgau M, Geiss L. 1999鈥?000 National Health And Nutrition Examination Survey. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999鈥?000 National Health And Nutrition Examination Survey. Diabetes Care. 2004;27:1591鈥?597. blank" title="It opens in new window">CrossRef <br> 33. Extension Protocol: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Available at: https://allhat.sph.uth.tmc.edu/Forms/ExtensionProtocol.pdf. Accessed April 28, 2014 <br> 34. Cimminiello C, Borghi C, Kownator S, PANDORA Study Investigators, et al. Prevalence of peripheral arterial disease in patients at non-high cardiovascular risk Rationale and design of the PANDORA study. BMC Cardiovasc Disord. 2010;10:35. blank" title="It opens in new window">CrossRef <br> 35. Dawson DL, Hiatt WR, Creager MA, Hirsch AT. Peripheral arterial disease: medical care and prevention of complications. Prev Cardiol. 2002;5:119鈥?30. blank" title="It opens in new window">CrossRef <br>
- 作者单位：Linda B. Piller MD, MPH (1) <br> Lara M. Simpson PhD (1) <br> Sarah Baraniuk PhD (1) <br> Gabriel B. Habib MD (2) <br> Mahboob Rahman MD (3) <br> Jan N. Basile MD (4) <br> Richard A. Dart MD (5) <br> Allan J. Ellsworth PharmD (6) <br> Herbert Fendley MD (7) <br> Jeffrey L. Probstfield MD (8) <br> Paul K. Whelton MB., MD, MSc. (9) <br> Barry R. Davis MD, PhD (1) <br> for the ALLHAT Collaborative Research Group <br><br>1. The University of Texas School of Public Health, 1200 Herman Pressler St., W-906, Houston, TX, 77030, USA <br> 2. Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA <br> 3. University Hospitals Case Medical Center, Louis Stokes Cleveland VA Medical Center, Case Western Reserve University, Cleveland, OH, USA <br> 4. Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA <br> 5. Marshfield Clinic Research Foundation, Marshfield, WI, USA <br> 6. University of Washington, Seattle, WA, USA <br> 7. AHEC Family Practice Center, Pine Bluff, AR, USA <br> 8. Division of Cardiology, University of Washington School of Medicine, Seattle, WA, USA <br> 9. Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA <br>
- ISSN：1525-1497
文摘